Sanofi (SNY) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $43.23, but acceptable to hold if already in. Reasons: Weak growth; Negative momentum.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib)... Read more
Hold if already holding. Not a fresh buy at $43.23, but acceptable to hold if already in. Reasons: Weak growth; Negative momentum. Chart setup: RSI 42 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Sanofi
Latest news
- Sanofi (SNY) Receives FDA Approval for Dupixent in Young Patients - GuruFocus — GuruFocus positive
- Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision - Benzinga — Benzinga negative
- FDA expands Sanofi’s Tzield use to children as young as 1 for type 1 diabetes delay (SNY:NASDAQ) - Seeking Alpha — Seeking Alpha positive
- Sanofi (NASDAQ:SNY) Announces Dividend Increase - $2.42 Per Share - MarketBeat — MarketBeat positive
- Sanofi’s Lunsekimig Delivers Positive Phase 2 Respiratory Data, Bolstering Asthma Pipeline - TipRanks — TipRanks positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $43.23, but acceptable to hold if already in. Reasons: Weak growth; Negative momentum. Chart setup: RSI 42 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $48.63 (+12.5%), stop $41.77 (−3.5%), A.R:R 2.5:1. Score 5.2/10, moderate confidence.
Take-profit target: $48.63 (+12.5% upside). Target $48.63 (+12.5%), stop $41.77 (−3.5%), A.R:R 2.5:1. Stop-loss: $41.77.
Weak growth; Negative momentum; Below 200-day MA.
Sanofi trades at a P/E of 18.4 (forward 8.2). TrendMatrix value score: 7.0/10. Verdict: Hold.
30 analysts cover SNY with a consensus score of 3.8/5. Average price target: $56.
What does Sanofi do?Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides...
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.